Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Myval TAVR valve associated with positive durability data after 4 years
Researchers have been spending more and more time evaluating the Myval TAVR valve from Indian medtech company Meril Life Sciences. The balloon-expandable device is available in some parts of the world, but not the United States.
Medicare now covers TriClip procedures for patients with symptomatic tricuspid regurgitation
CMS has finalized a new national coverage determination for T-TEER, sometimes known as transcatheter tricuspid valve repair. Abbott's TriClip is the only device approved by the FDA for T-TEER, but other treatment options are under development.
New TAVR valve from MiRus linked to positive early outcomes
The Siegel TAVR valve includes no nickel or cobalt. In fact, its frame was built using special alloys specifically developed by MiRus.
Cusp overlap technique improves TAVR outcomes, new meta-analysis confirms
The new study, based on 14 different clinical trials, highlights why so many care teams have already adopted the cusp overlap technique when implanting self-expanding TAVR valves.
At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving
Has the success of TAVR and other interventional techniques had a negative impact on surgical valve innovation? Two surgeons shared their concerns in a new commentary.

Permanent pacemaker implantation after mitral valve surgery: Exploring the impact on long-term survival

PPMI after aortic valve surgery is known to increase certain risks for patients, but its impact after mitral valve procedures is unclear. A team of researchers aimed to learn more, tracking data from more than 4,500 patients.

Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards

Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.

Topaz transcatheter tricuspid valve replacement (TTVR) system TriCares

Cardiologist shares positive first-in-human data on TriCares TTVR device

The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.

Early TAVR or SAVR in asymptomatic patients linked to improved survival, reduced costs

Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.

LVOT modification during robotic mitral valve repair limits complications

While LVOT modification does make these procedures longer, it can help high-risk patients avoid systolic anterior motion.

Medtronic gains a key approval for Evolut TAVR valves

More patients can now undergo redo TAVR with a Medtronic valve than ever before.

Same-day discharge after TAVR linked to positive outcomes

When low-risk patients undergo transfemoral TAVR, they may be able to go home without spending a single night at the hospital.

Edwards Lifesciences SAPIEN 3 Ultra TAVR valve

Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes

Each valve was associated with certain benefits, but one-year outcomes were largely similar.

Structural Heart Disease

Myval TAVR valve associated with positive durability data after 4 years

Medicare now covers TriClip procedures for patients with symptomatic tricuspid regurgitation

New TAVR valve from MiRus linked to positive early outcomes

Cusp overlap technique improves TAVR outcomes, new meta-analysis confirms

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving